• Plexāā

  Participated · Equity · Jul 2025

  Plexāā is a UK-based MedTech company whose flagship product, BLOOM43, is a fully wearable medical device and companion app designed to supraphysiologically precondition skin ahead of breast cancer surgery and reconstruction. BLOOM43 uses intermittent thermal preconditioning to trigger heat-shock proteins, causing vasodilation and increased blood flow; proof-of-concept clinical trials have shown reductions in wound-healing complications. The device and app have demonstrated improvements in patient experience and surgical readiness, and the company has secured multiple partners for an imminent U.S. commercial launch. Plexāā plans to expand the BLOOM43 platform into additional surgical specialties, including obstetrics (C-sections), orthopaedics, and general and vascular surgery. Financially, Plexāā recently closed a $4.5 million funding extension and has received over $1.6 million in NIHR i4i grant funding plus $1.3 million from Thena Capital, strengthening its position ahead of a planned Series A.

• Adona Medical

  Led · Series C · Jul 2024

  Adona Medical is a pre-clinical medical technology company focused on solutions for advanced heart failure. It is developing an adjustable interatrial shunt with integrated bi-atrial pressure monitoring alongside remote patient monitoring components as part of a heart failure management platform. The platform is investigational and not approved for use in the U.S. or elsewhere. The company plans to use newly raised capital to further product development and to initiate clinical use of the adjustable interatrial shunt and monitoring capabilities. Adona Medical raised $33.5M in a Series C financing to support those plans. The company is a Los Gatos, CA–based Shifamed portfolio company led by CEO Brian Fahey. Adona Medical is a pre-clinical stage medical technology company developing a next-generation heart failure management platform. The company is led by CEO Brian Fahey and is a privately held portfolio company of Shifamed LLC. Its core work focuses on next-generation solutions for patients with advanced heart failure. Adona intends to use new funding to complete product development and to support further evaluation of its platform. The article does not provide operating metrics such as revenue or user counts. Adona is based in Campbell, California. Adona Medical focuses on advanced interventional approaches for heart failure. The company is a privately held portfolio company of medical innovation hub Shifamed LLC and is based in Campbell, CA. It raised $2.5M in seed financing to advance product development and expand its intellectual property portfolio. The round was funded exclusively by select Shifamed accredited angel investors. Leadership includes newly appointed CEO Brian Fahey and Chairman Amr Salahieh. Fahey joins Adona with over 15 years of medtech leadership and product development experience.

No current team members are available.